Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

Portela becomes first mAb therapy with a three-month dosing interval approved for the alleviation of pain associated with OA ...